ACRS

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).

Wall Street analysts forecast ACRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRS is 9.25 USD with a low forecast of 6.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aclaris Therapeutics Inc revenue for the last quarter amounts to 3.30M USD, decreased -24.09 % YoY.

Aclaris Therapeutics Inc. EPS for the last quarter amounts to -0.12 USD, increased 9.09 % YoY.

Aclaris Therapeutics Inc (ACRS) has 64 emplpoyees as of December 15 2025.

Today ACRS has the market capitalization of 352.12M USD.